CSL
655 Elizabeth Street, Melbourne, VIC, 3000, Australia
Overview
CSL Limited is a public company which is a parent company of the CSL Group. CSL business activities operate in the Human Health, JRH Biosciences, Animal Health and ZLB Plasma Services operations. CSL limited develops, manufactures and markets pharmaceutical products of biological origin. The company' s business is: - Health care; - Life-saving products derived from human plasma; - Pharmaceuticals and diagnostics essential to health; - Cell culture reagents for the pharmaceutical industry; - Veterinary vaccines and diagnostics to protect livestock and companion animals.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Health Diagnostics
- Medical
Investment portfolio
- Denteric
Led · Series A · Feb 2022
Denteric was established to develop and commercialise a Porphyromonas gingivalis (Pg) vaccine program originating from the University of Melbourne in collaboration with CSL. The company is advancing a therapeutic vaccine intended to treat moderate to severe periodontitis, a debilitating gum disease that affects roughly one in three adults globally and is linked to diabetes, heart disease, rheumatoid arthritis, dementia and certain cancers. There are currently no cures for periodontitis and existing treatments are described as archaic and painful. Denteric has received a $14 million Series A to progress the Pg vaccine research program. The funds will support work toward commencing the company’s first human clinical trial, planned in the next two to three years. The program and company are closely tied to the University of Melbourne’s Centre for Oral Health Research and CSL, reflecting continued public–private collaboration within the Melbourne biomedical precinct.